Vitamin E Succinate Emulsion for Docetaxel Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations for intravenous delivery of docetaxel are plagued by toxicity due to allergenic solvents and excipients, instability, and the need for large amounts of pharmaceutically unsafe components, particularly due to docetaxel's high lipophilicity and instability in water.
Innovation Solution
Development of an oil-in-water emulsion stabilized by vitamin E succinate (VES) with submicron droplet size and specific zeta potential, allowing for a high drug-to-oil ratio and stability, enabling the formulation to be dried into a solid composition that can be rehydrated for injection, using a double-homogenization technique.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If docetaxel is formulated with polysorbate 80 as solubilizer, then solubility is improved, but toxicity increases due to severe allergic and hypersensitivity reactions
Solution Approach 1:
The patent removes the toxic polysorbate 80 solubilizer from the formulation and replaces it with a safer alternative system consisting of phospholipids and alcohol, thereby eliminating the harmful allergic reactions while maintaining docetaxel solubility
Solution Approach 2:
The patent changes the chemical parameters of the solubilization system by replacing polysorbate 80 with phospholipids and alcohol, fundamentally altering the formulation composition to achieve both solubility and safety requirements
2Ease of operation
If docetaxel is formulated in water-based solutions, then administration is simplified, but stability deteriorates due to rapid hydrolysis of the N-tert-butyl ester group
Solution Approach 1:
The patent introduces phospholipids as an intermediary substance that forms a protective interface between the water-based administration medium and the lipophilic docetaxel, preventing direct water contact and hydrolysis while enabling intravenous delivery
Solution Approach 2:
The patent creates a composite formulation system combining phospholipids, alcohol, and docetaxel in specific ratios, forming a stable emulsion or micellar structure that protects the drug from hydrolysis while maintaining ease of administration
3Stability of the object's composition
If large amounts of phospholipids or oil are used to stabilize emulsion, then stability is improved, but safety deteriorates due to pharmaceutically unsafe amounts of excipients
Solution Approach 1:
The patent optimizes the concentration parameters of phospholipids and alcohol within specific ranges (phospholipids 0.1-10%, alcohol 1-20%), achieving stable emulsion formation with minimal safe amounts of excipients, thereby maintaining both stability and safety
4Quantity of substance
If conventional solubilization methods are used for docetaxel, then solubility is improved, but the formulation contains toxic excipients such as ethanol, DMA, DMSO, propylene glycol, and n-methylpyrrolidon
Solution Approach 1:
The patent extracts and removes all toxic excipients (ethanol, DMA, DMSO, propylene glycol, n-methylpyrrolidon) from the formulation and replaces them with safe pharmaceutical excipients (phospholipids and alcohol), achieving solubility without toxicity
Solution Approach 2:
The patent converts the inherent lipophilicity of docetaxel, which causes solubility problems, into a benefit by utilizing phospholipids that naturally interact with lipophilic substances, forming stable emulsions without requiring toxic co-solvents
Data Source
AI summary
The present invention provides vitamin E succinate (VES)-stabilized compositions, methods for the preparation thereof and methods useful for the in vivo delivery of substantially water insoluble and optionally chemically unstable pharmacologically active agents (such as docetaxel).